TRAIL mutant membrane penetrating peptide alike (TMPPA) TRAIL‑Mu3 enhances the antitumor effects of TRAIL in vitro and in vivo.
The aim of the present study was to prepare a tumor necrosis factor ligand superfamily member 10 (TRAIL) mutant membrane penetrating peptide alike (TMPPA), TRAIL‑Mu3, and to investigate its antitumor effects in colorectal cancer in vitro and in vivo. The pMD19/TRAIL plasmid with designed primers was amplified to construct the target gene; it was ligated with an expression plasmid and the expression was confirmed. Subsequently, TRAIL‑Mu3 was purified and further confirmed by western blot analysis. Immunofluorescence analysis was used to detect the distribution of TRAIL‑Mu3 in colorectal cancer cells. In addition, the present study investigated the antitumor effects of TRAIL‑Mu3 on colorectal cancer in vitro and in vivo. A novel TMPPA, TRAIL‑Mu3, was synthesized in the present study. Following a series of detection experiments, it was confirmed that the TRAIL‑Mu3 gene was obtained and was able to express TRAIL‑Mu3 successfully. The immunofluorescence analysis demonstrated that TRAIL‑Mu3 exhibited a markedly enhanced affinity to the colorectal cancer cell surface. In addition, TRAIL‑Mu3 exerted stronger antitumor effects, compared with TRAIL, on colorectal cancer in vitro and in vivo.